Caribou Biosciences, Inc. (CRBU)
0.2843
-0.03
(-8.44%)
USD |
NASDAQ |
Nov 20, 16:00
0.2843
0.00 (0.00%)
After-Hours: 20:00
Caribou Biosciences Enterprise Value : -37.75M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | -37.75M |
| November 19, 2026 | -34.92M |
| November 18, 2026 | -33.23M |
| November 17, 2026 | -31.65M |
| November 16, 2026 | -30.35M |
| November 13, 2026 | -29.36M |
| November 12, 2026 | -27.39M |
| November 11, 2026 | -26.25M |
| November 10, 2026 | -24.12M |
| November 09, 2026 | -23.11M |
| November 06, 2026 | -19.99M |
| November 05, 2026 | -23.92M |
| November 04, 2026 | -20.45M |
| November 03, 2026 | -18.83M |
| November 02, 2026 | -20.94M |
| October 30, 2026 | -22.74M |
| October 29, 2026 | -20.39M |
| October 28, 2026 | -15.59M |
| October 27, 2026 | -18.69M |
| October 26, 2026 | -15.29M |
| October 23, 2026 | -10.90M |
| October 22, 2026 | -7.961M |
| October 21, 2026 | -9.647M |
| October 20, 2026 | -12.39M |
| October 19, 2026 | -18.33M |
| Date | Value |
|---|---|
| October 16, 2026 | -17.70M |
| October 15, 2026 | -18.26M |
| October 14, 2026 | -18.75M |
| October 13, 2026 | -17.68M |
| October 12, 2026 | -14.78M |
| October 09, 2026 | -18.74M |
| October 08, 2026 | -16.47M |
| October 07, 2026 | -1.760M |
| October 06, 2026 | 54.16M |
| October 05, 2026 | 60.10M |
| October 02, 2026 | 63.34M |
| October 01, 2026 | 63.34M |
| September 30, 2026 | 68.74M |
| September 29, 2026 | 45.78M |
| September 28, 2026 | 44.72M |
| September 25, 2026 | 45.78M |
| September 24, 2026 | 46.84M |
| September 23, 2026 | 51.08M |
| September 22, 2026 | 56.38M |
| September 21, 2026 | 52.14M |
| September 18, 2026 | 52.14M |
| September 17, 2026 | 53.20M |
| September 16, 2026 | 46.84M |
| September 15, 2026 | 48.96M |
| September 14, 2026 | 51.08M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anavex Life Sciences Corp. | -63.50M |
| Vaxcyte, Inc. | 7.199B |
| Foghorn Therapeutics, Inc. | -9.218M |
| Bolt Biotherapeutics, Inc. | 16.47M |
| Connect Biopharma Holdings Ltd. | 16.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.61M |
| Revenue (Quarterly) | 1.607M |
| Total Expenses (Quarterly) | 28.22M |
| EPS Diluted (Quarterly) | -0.2475 |
| Gross Profit Margin (Quarterly) | 63.29% |
| Profit Margin (Quarterly) | -1.66K% |
| Earnings Yield | -362.2% |
| Normalized Earnings Yield | -362.22 |